5-Azacytidine
5-Azacytidine (also known as 5-AzaC), a compound belonging to a class of cytosine analogues, is a DNA methyl transferase (DNMT) inhibitor that exerts potent cytotoxicity against multiple myeloma (MM) cells, including MM.1S, MM.1R, RPMI-8266, RPMI-LR5, RPMI-Dox40 and Patient-derived MM, with the half maximal inhibition concentration IC50 values of 1.5 μmol/L, 0.7 μmol/L, 1.1 μmol/L, 2.5 μmol/L, 3.2 μmol/L and 1.5 μmol/L respectively [1].
5-Azacytidine incorporates into cellular DNA and/or RNA, subsequently sequesters DNMT and forms a covalent bond between C6 of 5-Azacytidine and cysteine thiolate of DNMTs resulting in depletion of DNMT activity in cells and demethylation of cellular DNA [1].
References:
[1] Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun; 6 (6): 1718-27.
- 1. Dandan Li, Lingyun Xia, et al. "Serine protease PRSS56, a novel cancer-testis antigen activated by DNA hypomethylation, promotes colorectal and gastric cancer progression via PI3K/AKT?axis." Cell Biosci. 2023 Jul 3;13(1):124. PMID: 37400936
- 2. Murakami S, Nemazanyy I, et al. "A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas." Dev Cell. 2019 Aug 12. pii: S1534-5807(19)30628-8. PMID:31447265
- 3. Zhang W, Chen F, et al. "Zscan4c activates endogenous retrovirus MERVL and cleavage embryo genes." Nucleic Acids Res. 2019 Jul 15. pii: gkz594. PMID:31304534
- 4. Yang JR, Shi MX, et al. "LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275." Eur Rev Med Pharmacol Sci. 2019 Mar; 23 (5): 2103-2111. PMID:30915755
- 5. Li Z, Luo J. "Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia." Cancer Manag Res. 2018 Nov 5; 10: 5349-5362. PMID:30464631
- 6. Li Z, Yang L, et al. "Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21." Biomed Pharmacother. 2018 May 14; 104: 181-192. PMID:29772439
- 7. Li Z, Luo J. "Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia." Biochem Biophys Res Commun. 2018 Jun 18; 501 (1): 64-72. PMID:29704505
- 8. Zhang X, Yang L, et al. "Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia." Br J Haematol. 2017 May 8. PMID:28480959
- 9. Yagyu, Shigeki, et al. "Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch." Molecular Therapy—Methods & Clinical Development 3 (2016).
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 244.2 |
| Cas No. | 320-67-2 |
| Formula | C8H12N4O5 |
| Solubility | insoluble in EtOH; ≥24.45 mg/mL in DMSO; ≥13.55 mg/mL in H2O with ultrasonic |
| Chemical Name | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one |
| SDF | Download SDF |
| Canonical SMILES | C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
Leukemia L1210 cells |
|
Preparation method |
The solubility of this compound in DMSO is >12.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. |
|
Reacting condition |
80 μM; 0~120 mins |
|
Applications |
In leukemia L1210 cells, 5-Azacytidine showed greater inhibition on DNA synthesis instead of RNA synthesis. After a 90-min preincubation, TdR-3H incorporation was inhibited by about 74%, whilst UR-3H incorporation was inhibited by only 32%. |
| Animal experiment [2]: | |
|
Animal models |
BDF1 mice bearing lymphoid leukemia L1210 cells |
|
Dosage form |
3 mg/kg; i.p.; q.d. |
|
Applications |
In BDF1 mice bearing lymphoid leukemia L1210 cells, 5-Azacytidine increased the mean survival time. Moreover, 5-Azacytidine significantly suppressed all enzymes activity in the polyamine-biosynthetic pathway. In addition, 5-Azacytidine inhibited accumulation of polyamines in leukemic mice. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9. [2]. Heby O, Russell DH. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine. Cancer Res. 1973 Jan; 33 (1): 159-65. |
|
| Description | 5-Azacytidine is an inhibitor of DNA methyltransferase. | |||||
| Targets | DNA methyltransferase | |||||
| IC50 | ||||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
